Cingulate Inc. Annual Report - Fiscal Year 2025 Review

Considering an investment in Cingulate Inc.? This summary breaks down the company's performance for Fiscal Year 2025 (ended December 31, 2025), as reported in its 10-K filing on March 13, 2026. We've translated the key details into plain English, focusing on what matters most to investors.

Business Overview

Cingulate Inc. is a clinical-stage biopharmaceutical company that develops innovative treatments for central nervous system (CNS) disorders, primarily Attention Deficit/Hyperactivity Disorder (ADHD). The company's strategy is to advance its lead product candidates, CTxOneThreeZeroOne and CTxOneThreeZeroTwo, through clinical trials and the regulatory approval process. Cingulate's business model involves researching, developing, and eventually commercializing its proprietary pharmaceutical products.

Financial Performance

As a development-stage biotech, Cingulate generated no significant revenue in Fiscal Year 2025, which is common for companies focused on research and development. The company reported a net loss of $45.2 million, an increase from $38.5 million in Fiscal Year 2024.

Higher research and development (R&D) expenses primarily drove this increase, rising to $32.1 million (from $25.0 million) as Cingulate accelerated its clinical programs. General and administrative (G&A) expenses also increased modestly to $13.5 million from $12.0 million. These figures show the company heavily invests in its pipeline to achieve future market success.

Risk Factors

Investing in Cingulate, like many biopharmaceutical companies, involves significant risks. The most critical factors to consider include:

• Clinical Trial Success: The company's future depends on successfully completing ongoing clinical trials and achieving positive outcomes for CTxOneThreeZeroOne and CTxOneThreeZeroTwo. Trial failures could severely impact its prospects.
• Regulatory Approval: Even with positive trial data, the U.S. Food and Drug Administration (FDA) might not approve its New Drug Application (NDA) for CTxOneThreeZeroOne or any future applications. Regulatory delays or rejections could be costly.
• Funding: Cingulate will require substantial additional capital to complete development, obtain regulatory approvals, and potentially commercialize its product candidates. Without this funding, Cingulate might delay or abandon programs.
• Competition: The ADHD market is competitive, with established players and new entrants. Cingulate's products may not achieve significant market acceptance even if approved.
• Intellectual Property: Protecting its patents and proprietary technology is crucial for maintaining a competitive edge.
• Product Liability: Risks associated with pharmaceutical products, including potential product liability claims.
• Reliance on Third Parties: The company depends on contract research organizations (CROs) for clinical trials and contract manufacturing organizations (CMOs) for product manufacturing.

Management Discussion & Analysis (MD&A) Highlights

The Management Discussion & Analysis (MD&A) section offers management's perspective on the company's financial condition and operations. Key highlights for Fiscal Year 2025 include:

• Results of Operations: The significant ramp-up in R&D activities primarily caused the increased net loss. This included advancing CTxOneThreeZeroOne towards New Drug Application (NDA) submission and starting the CTxOneThreeZeroTwo Phase 3 trial. G&A expenses also rose to support growing operations.
• Liquidity and Capital Resources: Management highlighted its proactive efforts to manage cash burn and secure additional financing. It used an At-The-Market (ATM) offering facility and convertible notes to fund ongoing operations and clinical development. The "going concern" warning, which indicates uncertainty about the company's ability to continue operating without further funding, emphasizes the critical need for continuous capital raising.
• Operational Milestones: Fiscal Year 2025 was a pivotal period for Cingulate's lead product candidates:
  • CTxOneThreeZeroOne (for ADHD): Cingulate submitted a New Drug Application (NDA) to the FDA in Q4 2025. This is a critical step toward potential market approval. Investors should watch for the anticipated Prescription Drug User Fee Act (PDUFA) date, expected in late 2026, which indicates when the FDA plans to make a decision on the application.
  • CTxOneThreeZeroTwo (for ADHD): Cingulate started a Phase 3 clinical trial in Q3 2025, actively enrolling patients. This advancement shows continued progress in bringing this therapy closer to patients.

Financial Health

As of December 31, 2025, Cingulate reported $12.8 million in cash and cash equivalents, a decrease from $28.5 million at the end of 2024. This reflects its substantial cash burn from R&D activities.

To manage its funding needs, the company used an At-The-Market (ATM) offering facility, raising approximately $15.0 million by selling common stock during the year. It also secured additional financing through convertible notes with Werth Family Investment Associates LLC and Streetville Capital LLC, adding $10.0 million in new capital.

The company's 10-K includes a "going concern" warning. This means Cingulate's current cash resources are insufficient to fund operations for the next 12 months without securing additional financing. This common disclosure for development-stage biotechs highlights its ongoing need to raise capital to sustain operations and advance its pipeline. The company has no significant long-term debt other than the recently issued convertible notes.

Future Outlook

The upcoming year is crucial for Cingulate. The FDA's decision on the CTxOneThreeZeroOne New Drug Application (NDA) and the continued progress of the CTxOneThreeZeroTwo Phase 3 trial will determine the company's trajectory. Success in these areas could lead to commercialization and significant growth, while setbacks would require further strategic adjustments and potentially more capital raises. The company's ability to secure additional financing is essential for its long-term viability and to achieve its strategic goals. Management expects significant R&D expenditures to continue as clinical trials progress and regulatory activities intensify.

Competitive Position

Cingulate operates in the highly competitive central nervous system (CNS) therapeutic market, particularly for ADHD. This market includes established pharmaceutical companies with approved products and significant resources, as well as other clinical-stage companies developing novel treatments. Cingulate aims to differentiate its product candidates through unique formulation and delivery mechanisms, offering improved efficacy, safety, or patient convenience compared to existing therapies. The company continues to advance its pipeline, seek strategic partnerships, and explore additional indications for its platform technology to maximize value and gain a competitive edge.

Corporate Details & Leadership

As of March 13, 2026, Cingulate reported 11,628,613 shares of common stock outstanding. The market value of common stock held by non-affiliates was approximately $19.4 million as of June 30, 2025. No major leadership changes were announced during the fiscal year. The filing notes an ongoing evaluation of executive roles and potential future appointments as the company evolves.